Crispr Therapeutics AG (CRSP) — Capital Reinvestment Ratio
Crispr Therapeutics AG (CRSP) has a Capital Reinvestment Ratio of 0.01x as of March 2024, meaning it reinvests 0% of its operating cash flow ($109.75 Million) in capital expenditures ($721.00K). Check tangible equity quality of Crispr Therapeutics AG to evaluate the tangible quality of the company's equity base.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Crispr Therapeutics AG Capital Reinvestment Ratio (2015–2021)
This chart tracks Crispr Therapeutics AG's Capital Reinvestment Ratio across 3 annual periods. For the full cash flow conversion analysis, see Crispr Therapeutics AG cash flow conversion.
Annual Capital Reinvestment Ratio for Crispr Therapeutics AG (2015–2021)
Year-by-year Capital Reinvestment Ratio for Crispr Therapeutics AG from 2015 to 2021. See CRSP FCF generation index to measure how efficiently the company converts operating cash flow to free cash.
| Year | Reinvestment Ratio | Operating CF (USD) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2021 | 0.15x | $538.97 Million | $81.70 Million | ▲ +28.5% |
| 2019 | 0.12x | $56.68 Million | $6.68 Million | ▲ +507.3% |
| 2015 | 0.02x | $59.43 Million | $1.15 Million | — |